Form 4: Fate Therapeutics Director Granted 55,000 Stock Options Under Compensation Policy

William H. Rastetter, a Director at Fate Therapeutics Inc., was granted 55,000 stock options with an exercise price of $1.32, vesting in 2026.

Summary

• William H. Rastetter, a Director of Fate Therapeutics, Inc. (FATE), was granted 55,000 stock options.
• The transaction date for this grant was May 29, 2025.
• The options have an exercise price of $1.32 per share.
• The options are exercisable on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• The options expire on May 29, 2035.
• The grant was made pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy, which provides for annual equity grants to non-employee directors on the date of the Annual Meeting of Stockholders.
• The vesting is subject to Mr. Rastetter's continued service on the Board of Directors.

Sentiment

Score: 7

Explanation: The document reports a routine, expected equity grant to a director, which is a positive sign of continued alignment and standard corporate governance, without indicating any negative or unexpected events.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The transaction is part of a pre-established compensation policy, indicating a structured approach to director remuneration.

Negatives

• No specific negative points are identified in this routine Form 4 filing.

Risks

• The vesting of the options is contingent upon the director's continued service on the Board of Directors, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options granted to the director are set to vest on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service, indicating a future milestone for the director's equity compensation.

Management Comments

• The transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industries where non-employee directors receive equity compensation, such as stock options, to align their interests with long-term company performance and shareholder value creation. This is a common mechanism for attracting and retaining experienced board members in growth-oriented sectors.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common compensation practice across the biotechnology and broader corporate landscape, aligning with industry standards for executive and board remuneration.
• The vesting schedule, tied to a future date or the next annual meeting, is typical for such grants, similar to practices observed at comparable biotech firms like Gilead Sciences (GILD) or Amgen (AMGN) for their non-executive directors.
• The exercise price of $1.32, while specific to this grant, would be evaluated against the stock's market price on the grant date to assess its 'in-the-money' or 'out-of-the-money' status, a standard metric for option grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to William H. Rastetter, a director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Board of Directors: Reinforces the compensation structure for non-employee directors, potentially aiding in retention and attraction of qualified board members.

Next Steps

• The stock options are expected to vest on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Fate Therapeutics, FATE, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Beneficial Ownership, Corporate Governance, Biotechnology